Sapience Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Cell-penetrating ATF5 polypeptides and uses thereof (US 10,316,077) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Nucleic acids for inhibiting expression of C3 in a cell (US 11,753,642) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Nucleic acids for inhibiting expression of PROS1 in a cell (US 11,820,971) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 3 fees due Jul 7 to 23, 2027 · next Jul 7
- 1 fee due Aug 27, 2027The maintenance fee for Nucleic acid linked to a trivalent glycoconjugate (US 11,912,993) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,913,945 | Nucleic acid linked to a trivalent glycoconjugate In force · From the USPTO record | In force | From the USPTO record | |
| US 11,912,993 | Nucleic acid linked to a trivalent glycoconjugate In force · From the USPTO record | In force | From the USPTO record | |
| US 10,316,077 | Cell-penetrating ATF5 polypeptides and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,015,198 | Products and Compositions In force · High confidence | In force | High confidence | |
| US 11,414,660 | Products and compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 11,987,794 | Products and compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 11,174,483 | Products and Compositions In force · High confidence | In force | High confidence | |
| US 11,319,537 | Nucleic Acids for Inhibiting Expression of Lpa in a Cell In force · High confidence | In force | High confidence | |
| US 12,054,717 | Nucleic Acids for Inhibiting Expression of Lpa in a Cell In force · High confidence | In force | High confidence | |
| US 10,525,100 | ATF5 Peptide Variants and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 20: 18 lapsed for an unpaid fee · 15 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 7 no status recorded